A New York City federal court has dismissed a proposed class action lawsuit against Bristol Myers Squibb that accused the ...

A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National ...

A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National ...

Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy. It is planned that the drug using the new technology will pass all the necessary clinical trials and ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as ...